Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Classement en actions
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Prix de l'action
$4.48
Capitalisation boursière
$4.99B
Changement (1 jour)
-5.20%
Changement (1 an)
-41.89%
Pays
CN
Échange Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Catégorie
Healthcare
Nombre d'actions en circulation pour Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Nombre d'actions en circulation au June 2026: 1.11B
Selon les derniers rapports financiers et le cours de l'action de Shenzhen Salubris Pharmaceuticals Co., Ltd., le nombre actuel d'actions en circulation est de 1.11B. À la fin de December 2024, l'entreprise avait 1.11B actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) de 2006 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2026 (TTM) | 1.11B | -0.34% |
| 2025 | 1.11B | 0.07% |
| 2024 | 1.11B | -0.13% |
| 2023 | 1.12B | 1.55% |
| 2022 | 1.10B | 2.90% |
| 2021 | 1.07B | 3.79% |
| 2020 | 1.03B | -1.35% |
| 2019 | 1.04B | -0.33% |
| 2018 | 1.05B | 0.14% |
| 2017 | 1.04B | -0.14% |
| 2016 | 1.05B | 0.00% |
| 2015 | 1.05B | 0.36% |
| 2014 | 1.04B | -0.37% |
| 2013 | 1.05B | -0.14% |
| 2012 | 1.05B | 0.17% |
| 2011 | 1.05B | 0.15% |
| 2010 | 1.04B | 22.89% |
| 2009 | 849.71M | 8.80% |
| 2008 | 780.97M | -0.36% |
| 2007 | 783.76M | 19.22% |
| 2006 | 657.38M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| 349.00M | -68.59% |
US
|
|
| 461.20M | -58.49% |
FR
|
|
| 334.63M | -69.88% |
JP
|
|
| 274.79M | -75.27% |
US
|
|
| - | - |
CH
|
